Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review

Yasser Sakr1,*, Manuela Giovini2, Marc Leone3, Giacinto Pizzilli4, Andreas Kortgen1, Michael Bauer1, Tommaso Tonetti4, Gary Duclos3, Laurent Zieleskiewicz3, Samuel Buschbeck1, V. Marco Ranieri4 and Elio Antonucci2

Abstract

Background: Preliminary reports have described significant procoagulant events in patients with coronavirus disease-2019 (COVID-19), including life-threatening pulmonary embolism (PE).

Main text: We review the current data on the epidemiology, the possible underlying pathophysiologic mechanisms, and the therapeutic implications of PE in relation to COVID-19. The incidence of PE is reported to be around 2.6–8.9% of COVID-19 in hospitalized patients and up to one-third of those requiring intensive care unit (ICU) admission, despite standard prophylactic anticoagulation. This may be explained by direct and indirect pathologic consequences of COVID-19, complement activation, cytokine release, endothelial dysfunction, and interactions between different types of blood cells.

Conclusion: Thromboprophylaxis should be started in all patients with suspected or confirmed COVID-19 admitted to the hospital. The use of an intermediate therapeutic dose of low molecular weight (LMWH) or unfractionated heparin can be considered on an individual basis in patients with multiple risk factors for venous thromboembolism, including critically ill patients admitted to the ICU. Decisions about extending prophylaxis with LMWH after hospital discharge should be made after balancing the reduced risk of venous thromboembolism (VTE) with the risk of increased bleeding events and should be continued for 7–14 days after hospital discharge or in the pre-hospital phase in case of pre-existing or persisting VTE risk factors. Therapeutic anticoagulation is the cornerstone in the management of patients with PE. Selection of an appropriate agent and correct dosing requires consideration of underlying comorbidities.

Keywords: SARS-CoV-2, COVID-19, Pulmonary embolism, Thromboprophylaxis, Venous thromboembolism

Introduction

Since the emergence of coronavirus disease-2019 (COVID-19) as a result of infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1], several reports have described significant procoagulant events, including life-threatening pulmonary embolism (PE), in these patients [2–45]. Abnormalities of various coagulation parameters were frequently reported [46, 47] and have been linked to poor prognosis [48]. Unfortunately, little is known about the epidemiology and the pathophysiologic mechanisms underlying COVID-19-associated PE because of the lack of large prospective studies in this context. Understanding these aspects is crucial for the early diagnosis and appropriate management of this potentially fatal complication. In particular, the optimal dosage and duration of prophylactic anticoagulation...
are major concerns. Indeed, PE was reported to occur in critically ill COVID-19 patients despite thromboprophylaxis [31], questioning the possible role of the implementation of higher dosage of thromboprophylaxis than those used in the standard practice. In this report, we review the current literature on the subject to define the epidemiology, possible underlying pathophysiologic mechanisms, and therapeutic implications of PE in relation to COVID-19.

Epidemiology and outcome of PE in COVID-19

As of May 24, 2020, 27 case reports describing the clinical characteristics of 30 patients with COVID-19-associated PE have been published (Table 1) [2–28]. The median age of these patients was 59 years (interquartile range (IQR) 44–68 years, range 17–84 years) and 18/30 patients were male. One-third of the cases had no comorbid conditions prior to ICU admission. There was no detectable source of PE in most of the cases (24 patients, 80%). Diagnosis of PE was made at a median of 11 days (IQR: 7–17, range: 4–22 days) from the onset of SARS-CoV-2 symptoms. In 20 patients (66.7%), PE was bilateral; the majority of cases were treated with LMWH. Only 8 patients (26.7%) had central PE, of which 2 patients died.

Few cohort studies have reported the epidemiology of PE in COVID-19 patients, irrespective of the severity of illness and need for hospital admission (Table 2). Most of these were retrospective cohorts [29, 30, 32–37, 39–42, 44] and probably underestimated the incidence of PE because of the lack of a systematic approach to screening for this complication. The epidemiologic estimates were also likely influenced by the relatively short follow-up periods and different severities of infection. In two large retrospective French cohorts, the incidence of PE among patients positive for SARS-CoV-2, regardless of whether they were or were not admitted to hospital, was 1.1 and 3.4%, respectively [29, 30]. Evidence of PE was found in 23–30% of patients who underwent CTA imaging. Interestingly, comorbid conditions were similar in patients with PE and those without [29, 30]. We may speculate, therefore, that the occurrence of PE maybe related, at least in part, to the progression and severity of COVID-19 illness and not only to the physiologic status prior to infection. Indeed, patients with COVID-19 infection and PE had higher d-dimer levels, indicating higher severity of illness and more pronounced inflammatory response, than those without PE [30].

The incidence of PE in hospitalized patients with COVID-19 has been reported to be around 1.9–8.9% [29, 33, 43, 44]. Again, the retrospective nature of the reported cohorts and the relatively short periods of follow-up may have underestimated the real incidence of PE. Critically ill COVID-19 patients requiring ICU admission seem to be at a higher risk of thromboembolic complications, especially PE, which may occur in up to 26.6% of these patients [36]. In a prospective observational study of 150 patients admitted to four ICUs in two French hospitals, PE occurred in 16.7% of patients despite thromboprophylaxis [31]. The authors also reported that thromboembolic events were more common in COVID-19 patients with acute respiratory distress syndrome (ARDS) compared to a propensity score-matched historic ARDS cohort, underscoring the unique procoagulant effect of COVID-19 compared to other ARDS etiologies. A retrospective cohort of 184 patients with COVID-19 admitted to ICUs in three hospitals in the Netherlands reported that PE occurred in 13.6% of the patients despite anticoagulant therapy [32]. Interestingly, the incidence of PE increased to 33.3% when the follow-up was increased from 1 to 2 weeks [39], at a time when heightened awareness of the common occurrence of PE may have led to a higher index of suspicion and more diagnostic procedures to detect this complication. Likewise, Poissy et al. showed that 20.6% of patients admitted to a French ICU had PE within a median of 6 days following ICU admission despite anticoagulation [35]. These authors also found that the frequency of PE in COVID-19 patients was twice as high as the frequency in patients admitted to the ICU in a control period as well as in 40 ICU patients with influenza.

The paucity of deep venous thrombosis (DVT) or other sources of VTE in COVID-19 patients with PE [31] may suggest that, at least in some cases, pulmonary thrombosis rather than embolism is the underlying lesion in these patients. Nonetheless, autopsy of 12 consecutive patients admitted to an academic medical center in Germany revealed DVT in 7 of 12 patients (58%) in whom VTE was not suspected before death [38]. The prevalence of DVT in COVID-19 patients may, therefore, have been underestimated because of the lack of repeated screening in these patients. The authors also reported that PE was the direct cause of death in one-third of patients, confirming the clinical relevance of this complication [38]. Another autopsy study in 11 COVID-19 patients found that death may be caused by the thrombosis observed in segmental and subsegmental pulmonary arterial vessels in all patients, despite the use of prophylactic anticoagulation [45]. Taken together, whereas the current evidence may not support the routine screening for DVT in COVID-19 patients as recommended by the International Society of Thrombosis and Haemostasis (ISTH) [49], high degree of clinical suspicion in diagnosing DVT should be adopted in these patients based on both clinical manifestations and laboratory data. Patients with otherwise unexplained deterioration in the clinical picture, those with local signs
Table 1 Published case reports describing patients with COVID-19 complicated by pulmonary embolism (PE)

| Authors (country) | Sex, age (years) | Time to PE (days)* | Comorbid conditions | Source of PE | Extent of PE | Therapy | Outcome, remarks |
|-------------------|------------------|--------------------|---------------------|--------------|-------------|---------|------------------|
| Danzi et al. (Italy) [2] | F, 75 | 10 | None | None | Bilateral | LMWH | NR |
| Cellina et al. (Italy) [3] | M, 60 | 13 | Overweight | None | Bilateral; left main pulmonary artery and right interlobar artery | NR | NR |
| Ullah et al. (USA) [4] | F, 59 | > 8 | Hypertension, type 2 diabetes mellitus | None | Bilateral; central and proximal segmental pulmonary artery and linear sellar PE | LMWH → Apixaban | Discharged after 1 week |
| Casey et al. (USA) [5] | M, 42 | 12 | None | None | Bilateral segmental; infarct in the right lower lobe | LMWH | Discharged home |
| Foch et al. (France) [6] | M, 50 | 7 | Recent long-haul flight | None | Middle lobe and segmental | LMWH | NR |
| Rotzinger et al. (Switzerland) [7] | M, 75 | 4 | None | None | Right middle lobar segmental | LMWH | NR |
| Fabre et al. (France) [8] | F, 45 | 7 | Obesity, hypertension | Clot in patent foramen ovale, DVT of left leg | Massive bilateral proximal PE | Surgical embolectomy, ECMO | Death |
| Sulemane et al. (UK) [9] | M, 60 | – | Hypertension, hypercholesterolemia | Small, highly mobile mural thrombus within RV free wall | Bilateral; inferior lingula and segmental branches to lateral segment of middle lobe | Thrombolysis | NR |
| Audo et al. (Italy) [10] | M, 59 | > 10 days | None | None | Massive bilateral, right atrium and left and right main pulmonary arteries | Surgical embolectomy | Transferred to a regular ward |
| Le Berre et al. (France) [11] | M, 71 | 17 | None | Thrombosis of right posterior tibial vein | Anterior basal branch of right inferior lobe pulmonary artery | LMWH | Survived |
| Jafari et al. (Iran) [12] | F, 50 | 7 | None | None | Large saddle PE | Heparin and antithrombotic treatment | Discharged home |
| Griffin et al. (USA) [13] | M, 52 | 18 | Smoker | None | Bilateral | LMWH → rivaroxaban | Discharged receiving supplemental oxygen |
| | F, 60 | 18 | Ovarian cancer post oophorectomy, DVT 18 years earlier | None | Multiple bilateral segmental and subsegmental PE | LMWH → rivaroxaban | Discharged receiving supplemental oxygen |
| | M, 68 | 22 | Hypertension, diabetes mellitus | None | Bilateral | LMWH | Favorable outcome |
| Martinelli et al. (Italy) [14] | F, 17 | 9 | Obesity, pregnancy | None | Segmental PE in the right superior lobe | LMWH | Discharged home, Urgent cesarean sections (29W) |
| Lushina et al. (USA) [15] | M, 84 | 14 | Hypertension | None | Bilateral lobar PE | LMWH; thrombectomy | Death on day 2 |
Table 1 (continued)

| Authors (country) | Sex, age (years) | Time to PE (days) | Comorbid conditions | Source of PE | Extent of PE | Therapy | Outcome, remarks |
|-------------------|-----------------|------------------|---------------------|-------------|-------------|---------|-----------------|
| Harsch et al. (Germany) [16] | F, 66 | > 7 | Atrial fibrillation | None | Bilateral pulmonary arterial emboli in the lower lobes | Apixaban | Discharged home |
| Ueki et al. (Switzerland) [17] | M, 82 | 7 | None | None | Thrombus in right pulmonary artery | NR | NR |
| Ioan et al. (Spain) [18] | M, 61 | 7 | Smoking, hypertension | None | Bilateral PE | NR | Discharged home |
| Bruggemann et al. (Netherlands) [19] | M, 57 | 14 | Peripheral arterial disease | None | Multiple PE in the right pulmonary artery and bilateral (sub)segmental PE | LMWH | NR |
| Perez-Girbes (Spain) [20] | M, 68 | NR | NR | NR | Right lobar PE and segmental PE in the right upper lobe | NR | Discharged home |
| Khodamoradi et al. (Iran) [21] | F, 36 | 5 | Pregnancy, 5 days after cesarean section | None | Right side interlobar artery, posterior basal segment, and the lingular branch | LMWH | Discharged home |
| Poggiali et al. (Italy) [22] | M, 64 | 27 | None | DVT | Left subsegmental PE | Fondaparinux/dapigatran | Discharged home |
| Marsico et al. (Spain) [23] | M, 32 | 14 | None | None | Bilateral segmental and subsegmental branches of pulmonary arteries | LMWH | Discharged home |
| F, 59 | 19 | Hypertension, hypothyroidism | None | Bilateral segmental and subsegmental branches of pulmonary arteries | LMWH | Discharged home |
| Schmiady et al. (Switzerland) [24] | F, 54 | 3 | HIT-II | Multiple thrombi in the inferior vena cava, the right atrium, and the pelvic veins | Central pulmonary artery with occlusion of the lower right and middle pulmonary artery | Argatroban, Thrombectomy, ECMO | NR |
| Polat and Bostancı (Turkey) [25] | F, 41 | NR | Diabetes mellitus | None | Bilateral central PE | r-tPA/heparin | Sudden death |
| Ahmed et al. (UK) [26] | F, 29 | 14 | Diabetes mellitus, obesity, pregnancy | None | Right lower lobe | NR | Death |
| Molina et al. (USA) [27] | M, 23 | NR | Nitrous oxide abuse | DVT | Saddle PE | r-tPA | NR |
| Vitali et al. (Italy) [28] | M, 70 | 22 | None | None | Bilateral lobar and segmental | LMWH | Discharged home |

DVT: deep venous thrombosis, F: Female, LMWH: low-molecular weight heparin, HIT: heparin-induced thrombocytopenia, M: male, NR: not reported, PE: pulmonary embolism, r-tPA: recombinant tissue plasminogen activator, UK: United Kingdom

* Since the initial SARS-CoV-2 symptoms
Table 2: Summary of cohort studies reporting the epidemiology and outcome of thromboembolic complications in patients with COVID-19

| Authors, year Country | Design | Number of patients | Incidence of PE | Remarks |
|-----------------------|--------|--------------------|-----------------|---------|
| Grillet et al. France [29] | Retrospective study SARS-CoV-2 according to +ve RT-PCR or high clinical suspicion | SARS-CoV-2 +ve: 2003 pts Hosp. adm.: 280 pts CTA performed: 100 pts | 23% (among patients with CTA) 8.9% (among hosp admissions) 1.1% (among all COVID-19 + ve pts) | Radiologic study, no clinical correlates Average time to CTA: 12 days PE pts.: ICU admissions, 74% MV: 65% No differences in comorbidities between PE and no PE Selection bias (only severe cases/clinical deterioration with CTA) |
| Leonard-Lorant et al. France [30] | Retrospective study 2 French hospitals | SARS-CoV-2 +ve: 961 pts COVID-19 with CTA: 106 pts (97 + ve RT-PCR, 9 high clinical suspicion) | 30% (among patients with CTA) 3.4% (among SARS-CoV-2 + ve pts) | PE pts.: ICU admissions, 75% PE: 22% main PA, 34% lobar, 28% segmental, 16% subsegmental No differences in comorbidities between PE and no PE Selection bias (only severe cases/clinical deterioration with CTA) D-Dimer levels associated with PE |
| Helms et al. France [31] | Prospective cohort 4 ICUs in 2 hospitals | 150 pts | 16.7% | Short follow-up in some patients (7 days) PE mostly men (24/25, mean age 62 years old) PE: 36% main PA, 32% lobar, 20% segmental and 12% subsegmental PE detected at a median of 5.5 days after ICU admission Thromboembolic events more common in COVID-19 ARDS compared to historic ARDS cohort All patients received at least standard dose thromboprophylaxis |
| Klok et al. Netherlands* [32] | Retrospective cohort ICUs in 3 hospitals | 184 pts | 13.6% | 31% thrombotic complications Age and coagulopathy were independent predictors of thrombotic complications Median duration of follow-up per patient was 7 days All patients received at least standard doses thromboprophylaxis |
| Lodigiani et al. Italy [33] | Retrospective single-center cohort | 388 pts (61 ICU pts) | 2.6% overall 4.2% (of 48 closed ICU cases) | Thromboprophylaxis was used in 100% of ICU patients and 75% of those on the general ward Incidence may have been highly under-estimated due to the low number of specific imaging tests performed |
| Litjos et al. France [34] | Retrospective cohort 2 ICUs | 26 pts | 23% | Duplex ultrasound performed as standard of care 31% (n = 8) of prophylactic anticoagulation and 69% (n = 18) of therapeutic anticoagulation |
| Poissy et al. France [35] | Retrospective cohort ICU | 107 pts | 20.6% | PE occurred within a median 6 days after ICU admission Despite a similar severity on admission to the ICU, the frequency of PE in COVID-19 patients was twice higher than the frequency in the control period and in 40 influenza patients All patients received at least standard doses thromboprophylaxis Low number of associated DVTs D-Dimer levels, plasma factor VIII activity, and factor Willebrand antigen levels were associated with a greater PE risk |
| Beun et al. Netherlands [36] | Retrospective cohort ICU | 75 pts | 26.6% | High-dose UFH of more than 35,000 IU/day was used in 4 patients with PE due to heparin resistance Factor VIII, fibrinogen, and D-dimer levels were elevated, while almost all of the antithrombin levels were within the normal range in all patients |
Table 2 (continued)

| Authors, year Country | Design | Number of patients | Incidence of PE | Remarks |
|-----------------------|--------|--------------------|-----------------|---------|
| Middeldorp et al. Netherlands [37] | Retrospective single-center cohort COVID-19 according to +ve RT-PCR or high clinical suspicion | 198 pts (75 ICU) | 6.6% overall 15% ICU | All patients received at least standard doses thromboprophylaxis Median follow-up duration was 15 days in ICU patients and 4 days in ward patients PE: 8% central, 7.7% segmental, 15% subsegmental High d-dimer levels, low lymphocytic count associated with thromboembolic manifestations |
| Wichmann et al. Germany [38] | Autopsy study COVID-19 according to +ve RT-PCR | 12 pts | 33.3% | DVT in 7 of 12 patients (58%) in whom venous thromboembolism was not suspected before death In all patients, SARS-CoV-2 RNA was detected in the lung at high concentrations 5 of 12 patients demonstrated high viral RNA titers in the liver, kidney, or heart |
| Klok et al. Netherlands* [39] | Retrospective cohort - ICUs in 3 hospitals | 184 pts | 35.3% | Increasing follow-up from 7 to 14 days increased the incidence of PE from 13.6 to 35.3% PE: 70.8% segmental or more proximal arteries, 29.8% subsegmental arteries |
| Bompard et al. France [40] | Retrospective cohort 2 Hospitals | 135 pts COVID-19 + CTA | 23.7% | Sixty-three pts (47%) were outpatients seen at the emergency department Twelve PE were diagnosed in outpatients at initial presentation whereas the remaining 17 were diagnosed in patients who had presented clinical deterioration during hospitalization PE: 31% proximal, 56% segmental, 13% multiple sub segmental pulmonary arteries 4 patients with PE died (13%) within a median of 26 days All patients received prophylactic anticoagulation |
| Thomas et al. UK [41] | Retrospective Single center | 63 pts | 7.9% | PE: 20% sub-segmental, 40% segmental, 20% multiple segmental and 20% in a main pulmonary artery None of the patients that developed thrombosis had a history of either active cancer or VTE Very short follow-up (median 8 days) |
| Poyiadj et al. USA [42] | Retrospective Multicenter | 328 pts COVID-19 + CTA | 22% | PE: 51% segmental, 31% lobar, 13% central, 5.5% subsegmental 28/122 (23%) of all patients that were on venous thromboprophylaxis developed a PE Statin therapy associated with lower and BMI > 30 kg/m²; d-dimer of 6 μg/mL with higher risk of developing PE |
| Galeano-Valle et al. Spain [43] | Prospective Single center | 785 pts COVID-19 | 1.9% | PE: 40% had intermediate–high risk PE and 60% patients had low risk PE Non-ICU setting, low severity of illness |
| Stoneham et al. UK [44] | Retrospective 2 hospitals | 274 pts Confirmed or highly suspected COVID-19 | 5.8% | White cell count, d-dimer, and fibrinogen associated with the occurrence of VTE in COVID-19 patients Almost all patients had an abnormal d-dimer result at baseline, defined as a d-dimer > 0.5 μg/mL Three patients were described to have resistance to anticoagulation |
| Lax et al. Austria [45] | Autopsy study | 11 pts | 100% | Ten of the 11 patients received prophylactic anticoagulant therapy; Venous thromboembolism was not clinically suspected antemortem in any of the patients Thrombosis of small and mid-sized pulmonary arteries was found in various degrees in all 11 patients and was associated with infarction in 8 patients |

ARDS: acute respiratory distress syndrome, CTA: angiographic computed tomography, DVT: deep venous thrombosis, ICU: intensive care unit, PA: pulmonary artery, PE: pulmonary embolism, pts: patients, MV: mechanical ventilation, RT-PCT: real-time reverse transcriptase polymerase chain reaction, UK: United Kingdom

* Same cohort, analysis updated to increase the follow-up period from 7 to 14 days
and symptoms of DVT, together with markedly elevated d-Dimer levels may be good candidates for diagnostic ultrasound assessment.

**Pathophysiology of PE in COVID-19**

The hypercoagulable state in COVID-19

The hypercoagulable state in COVID-19 was confirmed in a study by Han et al., in which higher levels of d-dimer, fibrinogen, and fibrinogen degradation products [46], prolonged prothrombin time (PT), international normalized ratio (INR), and thrombin time (TT) were also noted in patients with COVID-19 [47]; these abnormalities have been associated with poor prognosis in patients infected with SARS-CoV-2 [48]. Oudkerk et al. suggest that the very high d-dimer levels observed in COVID-19 patients are not only secondary to systemic inflammation, but also reflect true thrombotic disease, possibly induced by cellular activation that is triggered by the virus [50]. Furthermore, Cui et al. demonstrated that a cut-off value of 3.0 μg/mL for d-dimer had sensitivity, specificity and negative predictive values of 76.9%, 94.9% and 92.5% to predict VTE, respectively [51]. After receiving anticoagulant therapy, the level of d-dimer decreased gradually, showing that d-dimer levels may not only predict thrombosis but also monitor the effectiveness of anticoagulant therapy. Nonetheless, d-dimer levels may not be a reliable predictor of VTE but rather a marker of poor overall outcome [4, 9] [52]. Indeed, Lionard-Lorant et al. showed that d-dimer greater than 2660 μg/L is highly sensitive (100%, 95% CI 88–100) but not specific (67%, 95% CI 52–79) to detect PE in COVID-19 patients [30]. Therefore, routine screening for VTE based on elevated d-dimer levels was not recommended in the most recent guidelines of the ISTH [49].

Viral infections may predispose to VTE [51], activating systemic inflammatory response that in turn causes an imbalance between procoagulant and anticoagulant effects [52]. Coagulation pathways and immune system are strictly linked. Clot formation should limit the loss of blood and immune components [53]. Meanwhile, a blood clot can slow down microorganism invasion of the circulation [53]. Indeed, immunocompromised individuals have been suggested to have had less pulmonary complications when infected with COVID-19 [53]. Thrombin and platelets play a key role in the relationship between immune system and coagulation. On the one hand, thrombin directly links the clotting pathways to the innate immune response [54]. On the other hand, various granular constituents of the platelets show antimicrobial and chemotactic properties [55]. The interaction between coagulation and inflammatory pathways in the bronchoalveolar compartment, also known as the “bronchoalveolar hemostasis” [56] could partially explain thrombotic complications in COVID-19 patients.

**Phenotypes and possible pathophysiologic mechanisms**

At least two main phenotypes of COVID-19 patients with thrombotic lung injury can be identified: patients affected by “ordinary” VTE and patients showing pulmonary microthrombosis (PMT). Since DVT or other sources of VTE were not consistently found in COVID-19 patients with PE, PMT could be the result of local hypercoagulability rather than secondary to embolization from the lower limbs [53]. Formation of thrombi in the microvasculature may be a part of the physiological effort to limit the viral load. Indeed, viral invasion induces an intense inflammation of the lungs which in turn triggers a local activation of hemostasis driven by the interaction between platelets and endothelium [53]. It has been speculated that a possible cornerstone of microthrombi generation during COVID-19 is related to endothelial cells’ dysfunction [57, 58].

Interestingly, the coagulation activation pattern in COVID-19 ARDS patients in the ICU was not the same as in non-COVID-19 ARDS patients [31]. Whereas d-dimers levels were less elevated, PT, activated partial thromboplastin time (aPTT), and AT were within normal ranges, and fibrinogen was higher. This pattern differs also from that observed in patients with septic shock, who frequently develop disseminated intravascular coagulation (DIC) [59]. Helms et al. reported that no COVID-19 patient was diagnosed with DIC using ISTH “overt” score [31]. The underlying mechanisms of COVID-19-induced coagulopathy may be, therefore, different from that reported in other patients with sepsis. This may also explain the different phenotypes observed in COVID-19 patients, with predominant thromboembolic manifestations rather than bleeding tendency.

Several mechanisms may contribute to a hypercoagulable state [60] and PMT during COVID-19 [46] (Fig. 1). First, the direct and indirect pathologic consequences of COVID-19, such as severe hypoxia, preexisting comorbidities, and associated organ dysfunction can predispose to hemostatic abnormalities, including DIC [47]. Hypoxia can predispose to thrombosis by increasing blood viscosity and via a hypoxia-inducible transcription factor-dependent signaling pathway [61]. The risk of VTE is also associated with individual patient-related risk factors, such as age, immobilization, obesity, past history of personal or familial VTE, cancer, sepsis, respiratory or heart failure, pregnancy, stroke, trauma, or recent surgery. ICU-specific risk factors may also contribute to this risk, including but not limited to sedation, immobilization, vasopressor administration, and use of central venous catheters [60]. Second, endothelial dysfunction,
von Willebrand factor (vWF) elevation, Toll-like receptor activation, and tissue-factor pathway activation [62] may induce proinflammatory and procoagulant effects through complement activation and cytokine release [50], resulting in a dysregulation of the coagulation cascade with the subsequent formation of intra-alveolar or systemic fibrin clots. This may be explained, at least in part, by the increased plasminogen activator inhibitor 1 (PAI-1) levels with subsequent decrease of the fibrinolytic activity in these patients [63]. Helms et al. analyzed the occurrence of thromboembolic events in all patients admitted to four French ICUs for COVID-19-associated ARDS [31]. They noted that vWF activity and vWF antigen (vWF:Ag) were considerably increased, as was factor VIII. Furthermore, 50 of the 57 patients tested (87.7%) had positive lupus circulating anticoagulants during their ICU stay. Third, the release of high plasma levels of proinflammatory cytokines (IL-2, IL-6, IL-7, IL-8, granulocyte colony-stimulating factor, interferon gamma-induced protein 10 (IP10), monocyte chemotactic protein-1 (MCP1), macrophage inflammatory protein 1A (MIP1A), and tumor necrosis factor (TNF-α)—the so-called “cytokine storm”, which is a common feature of sepsis—cause secondary development of hemophagocytic lymphohistiocytosis with activation of blood coagulation, increased risk of intravascular microthrombosis and secondary local consumption coagulopathy [50], promoting the occurrence of VTE. Finally, the interactions between different types of blood cell (macrophages, monocytes, endothelial cells, platelets and lymphocytes) could play a critical role in the procoagulant effect of viral infections. For example, platelet activation upon antigen recognition

![Fig. 1 Schematic representation of the possible pathophysiologic mechanisms underlying pulmonary embolism (PE) in patients with coronavirus disease-2019 (COVID-19). CD: CD receptor, CKD: chronic renal failure, COPD: chronic obstructive pulmonary disease, FDP: fibrin degradation products, GCSF: granulocyte-colony stimulating factor, HF: heart failure IFN: interferon, IL: interleukin, IP: interferon-gamma induced protein, MCP: monocyte chemotactic protein, MIP: macrophage inflammatory protein, NK: natural killer cells, PT: prothrombin time, SARS CoV-2: acute respiratory syndrome coronavirus 2, TNF alpha: tumor necrosis factor alpha](image)
may facilitate the pathogen’s clearance by white blood cell activation and clot formation [62]. This may be modulated by the neutrophil extracellular traps (NETs), which are induced by platelets and play an important role in sepsis-associated hypercoagulability [64]. In agreement with this assumption, Middeldorp et al. found that white blood cell count, higher neutrophil-to-lymphocyte ratio and a higher D-dimer level are independent risk factors associated with VTE [37].

The role of endothelial injury
Endothelial cells represent almost a third of the cells in the broncho-alveolar units [65]. Endothelial dysfunction refers to a systemic condition in which the endothelium loses some of its physiological properties such as promoting vasodilation, fibrinolysis, and anti-aggregation [65]. This condition could be induced in COVID-19 patients through general and virus-related factors. Comorbid conditions, such as hypertension, diabetes and acute kidney injury are usually linked to endothelial damage and may, therefore, promote COVID-19-related complications [65]. Virus-related factors may also induce endothelial damage through direct viral penetration in endothelial cells, the effects of cytokines on the endothelium, and the release of von Willebrand factor by endothelial cells. Endothelial cells possess the key receptors for the SARS-CoV-2 (i.e., the angiotensin-converting enzyme-2 receptors), that facilitate viral penetration [66]. They also express other receptors shared with SARS-CoV-2, such as serine protease 2 and sialic acid receptors [58]. Accordingly, endothelial cell infection results in some cytopathic modifications following viral penetration. In particular, vascular obliteration and thrombosis of small and middle size vessels are common findings in PMT secondary to COVID-19. Furthermore, the proinflammatory cytokines released in patients with COVID-19 promote vascular endothelial cell apoptosis, PMT, vascular leakage, alveolar edema, and ultimately hypoxia [66]. Proinflammatory cytokines can also increase the expression of adhesion molecules that in turn results in endothelial activation, procoagulant effects and pro-adhesive changes [67]. All these molecular changes can impaire microvascular flow and, consequently, alter ventilation/perfusion ratio. It has been also postulated that endothelial damage and PMT could be induced by an imbalance between insufficient ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) and excessive exocytosis of ultra large von Willebrand factor multimers (ULVWF) from Weibel–Palade bodies present in endothelial cells [57]. ULVWF are anchored to the endothelial surface and can recruit platelets inducing microthrombogenesis [57]. Subsequently, platelets are rapidly activated causing platelet aggregation and leukocytes recruitment in a P-selectin-dependent manner [57]. These aggregates continue to grow until they become sufficiently large to induce extended PMT.

Therapeutic implications
The accumulating evidence suggests that PE is a significant complication in patients with COVID-19, so that indications and modalities for prophylactic and therapeutic use of antithrombotic agents should be revisited. Preliminary data from 449 consecutive patients with severe COVID-19 demonstrated that prophylactic doses of heparin were associated with improved survival in a subgroup of patients meeting criteria for sepsis-induced coagulopathy or with markedly elevated D-dimer levels [68]. The ISTH and the American Society of Hematology (ASH) [47, 49, 60, 69] have recently recommended that a prophylactic dose of LMWH (40 mg qd) [70] or subcutaneous unfractionated heparin (5000 IU tid)—should be started in all suspected or confirmed COVID-19 patients admitted to the hospital. In patients with known heparin-induced thrombocytopoenia, fondaparinux [70, 71], which was found to be effective in reducing sepsis-derived coagulopathy in an animal model [72], should be used. If pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (e.g., intermittent pneumatic compression) should be considered in immobilized patients [47]; combined pharmacologic and mechanical prophylaxis is not generally recommended [71]. Although limited data are available, it is reasonable to consider pharmacological thromboprophylaxis in patients admitted to hospital with COVID-19 infection, even in pregnant women, since they are likely to be at an increased risk of VTE [47]. The use of and intermediate dose of LMWH (e.g., enoxaparin 4000 IU subcutaneously every 12 h) can be considered on an individual basis in patients with multiple risk factors for VTE [73] and in critically ill patients due to the higher incidence of PE in this population [29–41]. In obese patients, higher weight-based doses may be needed, with doses of 7500 IU UFH three times daily or enoxaparin 40 mg twice daily [74, 75]. Figure 2 represents a flow diagram of the recommended procedure for initiating thromboprophylaxis in patients with coronavirus disease-2019.

Therapeutic anticoagulation is the cornerstone in the management of patients with PE. Selection of an appropriate agent and correct dosage requires consideration of the underlying comorbidities, such as renal or hepatic dysfunction, thrombocytopenia, and gastrointestinal tract function [47]. Zhai et al. recommend LMWH (e.g., subcutaneous enoxaparin 100 IU/kg, twice daily or 150 IU/kg once daily, or nadroparin 86 IU/kg twice daily) as a first-line treatment [76]. In severe renal impairment, or if it is expected that invasive procedures will be
required, intravenous UFH followed by the subcutaneous route is more appropriate, with regular monitoring for anticoagulation dose adjustment. Direct oral anticoagu-
lants (DOACs) are an option only after the acute phase in stable patients, with the well-known benefits of lack of need for monitoring, which facilitates timely discharge from the hospital and outpatient management. How-
ever, a potential risk of DOACs, especially in the setting of organ dysfunction, may include clinical deterioration and lack of effective reversal agents at some centers [47]. Geert-Jan Geersing et al. provided a guidance document for switching from vitamin K antagonists (VKAs) to a DOAC in current emergency settings [77]. They underscore the need to switch with care and caution, and the importance of not making this choice just for simplicity, because it may contribute to errors like overlapping periods of anticoagulation, terminating VKA without correctly starting DOACs, and lack of explanation to the patient for the reasons for such drug changes, thus create a potential risk for thromboembolism or bleeding [78]. The use of catheter-directed therapies during the current outbreak should be limited to the most critical situations.
[47]. Recurrent PE despite optimal anticoagulation and clinically significant VTE in the setting of absolute contraindications to anticoagulation would be among the few scenarios in which placement of an inferior vena cava filter may be considered [47, 79], and even in these cases, anticoagulation should be resumed as soon as feasible. In patients requiring therapeutic doses of LMWH or receiving a DOAC, renal function should be monitored and anti-factor Xa or plasma DOAC levels should be monitored.

Intermediate-risk hemodynamically stable patients (intermediate–low risk or intermediate–high risk PE according to the European Society of Cardiology (ESC) classification; sub-massive PE according to prior classifications) should be managed initially with anticoagulation and close monitoring. If the condition suddenly worsens and there are signs of overt hemodynamic instability (massive or high-risk PE with hypotension or sudden cardiac arrest) and evidence on bedside echocardiography of new onset increased right-ventricular load or pulmonary arterial hypertension, thrombolytic therapy should be initiated urgently [47, 76]. In case of refractory shock or cardiac arrest, extra corporeal membrane oxygenator (ECMO) could be an option, in combination with surgical embolectomy or catheter-directed treatment, as rescue initiatives [76].

Since the procoagulant effect of COVID-19 may extend some weeks after hospital discharge of apparently stable, asymptomatic patients. It would be prudent, therefore, to have a high degree of clinical suspicion of PE in COVID-19 patients readmitted to the hospital after surviving an initial hospitalization. Decisions about extending prophylaxis with LMWH after hospital discharge from acute medical illness should be made by balancing the reduced risk of VTE with the risk of increased bleeding events, including major bleeding. In the absence of high-quality data, pharmacological prophylaxis in this context should be reserved for patients at highest risk, including those with limited mobility and history of prior VTE or active malignancy [47]. As recommended by the Italian Society on Thrombosis and Haemostasis (SISET), prophylactic anticoagulation should be maintained at home for 7–14 days after hospital discharge or in the pre-hospital phase during home self isolation, in case of pre-existing or persisting VTE risk factors (i.e., reduced mobility, body mass index (BMI) > 30, previous VTE, active cancer, etc.) [73].

Summary and conclusions

Patients with COVID-19 are at increased risk of developing PE which may occur in up to one-third of critically ill COVID-19 patients requiring ICU admission. Thromboprophylaxis should therefore be started in COVID-19 patients admitted to the hospital and intermediate therapeutic doses of anticoagulants can be considered in patients requiring ICU admission or those with multiple risk factors for VTE. Extending thromboprophylaxis after hospital discharge or in the prehospital phase during home self isolation should be done according to a meticulous risk/benefit assessment, balancing the reduced risk of VTE with the risk of increased bleeding events. Therapeutic anticoagulation is the cornerstone in the management of patients with PE. Selection of an appropriate agent and correct dosage requires consideration of underlying comorbidities and organ dysfunction.

Abbreviations

ADAMTS-13: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aPTT: Activated partial thromboplastin time; ARDS: Acute respiratory distress syndrome; ASH: American Society of Hematology; BMI: Body mass index; ECMO: Extra corporeal membrane oxygenator; CTA: Computer tomographic angiography; COVID-19: Corona virus disease-2019; DIC: Disseminating intravascular coagulation; DOAC: Direct oral anticoagulants; DVT: Deep vein thrombosis; ESC: European Society of Cardiology; ICU: Intensive care unit; IL: Interleukin; INR: International normalized ratio; IP: Interferon-gamma induced protein; ISTH: International Society on Thrombosis and Haemostasis; I.U.: International unit; IQ: interquartile range; LMWH: Low molecular weight heparin; MCP: Monocyte chemotactic protein; MIP: Macrophage inflammatory protein; NETs: Neutrophil extracellular traps; PMT: Pulmonary microthrombosis; PT: Prothrombin time; PAI-1: Plasminogen activator inhibitor 1; PE: Pulmonary embolism; RT-PCR: Real-time reverse transcription polymerase chain reaction; r-PA: Recombinant tissue-type plasminogen activator; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; SISET: Italian Society on Thrombosis and Haemostasis; TT: Thrombin time; ULVWF: von Willebrand factor multimers; VTE: Venous thromboembolism; VKA: Vitamin K antagonist; vWF: Von Willebrand factor; vWF:Ag: Von Willebrand factor; vWF antigen.

Acknowledgements

None.

Authors’ contributions

YS, IA, VMR, AK, MB, and ML, designed the scientific work. YS, SB, EA, and MG reviewed the literature. YS, EA, MG, ML, GP, TT, GD, and LZ wrote the first draft of the manuscript. All the authors reviewed and revised, the submitted manuscript. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they do not have conflict of interests in relation to this manuscript.

Author details

1 Dept. of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07743 Jena, Germany. 2 Intermediate Care Unit, Emergency Department, Ospedale Guglielmo da Saliceto, Racenza, Italy. 3 Service d’Anesthésie et de Réanimation, Aix Marseille Université, Assistance Publique Hôpitaux Universitaires de Marseille, Hôpital Nord, Marseille, France. 4 Service d’Anesthésie et de Réanimation, Aix Marseille Université, Assistance Publique Hôpitaux Universitaires de Marseille, Hôpital Nord, Marseille, France.
References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.

2. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41:1858.

3. Cellina M, Oliva G. Acute pulmonary embolism in a patient with COVID-19 pneumonia. Diagn Interv Imaging. 2020;101:325–6.

4. Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Rep. 2020;2:1379–82.

5. Casey K, Iteem A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Ann Emerg Med. 2020;73:1544.e1–3.

6. Foch E, Allou N, Vitty T, Massle I, Allyn J, Andre M, et al. Pulmonary embolism in returning traveler with COVID-19 pneumonia. J Travel Med. 2020;27:taa063.

7. Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography. Thromb Res. 2020;190:58–9.

8. Fabre O, Rebet O, Carajulu I, Radotiu M, Gautier L, Hysi I. Severe acute proximal pulmonary embolism and COVID-19: a word of caution. Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athorac Surg. 2020.04.005.

9. Sulemane S, Baltabaeva A, Barron AJ, Chester R, Rahman-Haley S. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient. Eur Heart J Cardiovasc Imaging. 2020;21:1054.

10. Audo A, Bonato V, Cavozza C, Maj G, Pittis G, Secco GG. Acute pulmonary embolism in SARS-CoV-2 infection treated with surgical embolectomy. Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athoracsurg.2020.04.013.

11. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging. 2020;101:321–2.

12. Jafri R, Cegolini L, Jafar I, Kashkai M, Otukesh B, Ghaedherijani BH, et al. Large saddle pulmonary embolism in a woman infected by COVID-19 pneumonia. Eur Heart J. 2020;41:2133–4.

13. Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, et al. Pulmonary embolism and increased levels of D-dimer in patients with coronavirus disease. Emerg Infect Dis. 2020;26(8):1941.

14. Martiniell I, Ferrera E, Gavaraile A, Erra R, Iurfaro E, Ossola M, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36–7.

15. Lushina N, Kuo JS, Shaikh HA. Pulmonary, cerebral, and renal thromboembolic disease associated with COVID-19 infection. Radiology. 2020;289:E181–3.

16. Hansch IA, Skiba M, Konturek PC. SARS-CoV-2 pneumonia and pulmonary embolism in a 66-year-old female. Pol Arch Intern Med. 2020;190:438–9.

17. Ueki Y, Otsuka T, Windecker S, Raber L. ST-elevation myocardial infarction associated in seriously ill patients? Arch Bronconeumol. 2020;56:34.

18. Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID-19 complicated by acute pulmonary embolism in returning traveler with COVID-19 pneumonia. J Travel Med. 2020;27:taa063.

19. Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography. Thromb Res. 2020;190:58–9.

20. Fabre O, Rebet O, Carajulu I, Radotiu M, Gautier L, Hysi I. Severe acute proximal pulmonary embolism and COVID-19: a word of caution. Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athorac Surg. 2020.04.005.

21. Sulemane S, Baltabaeva A, Barron AJ, Chester R, Rahman-Haley S. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient. Eur Heart J Cardiovasc Imaging. 2020;21:1054.

22. Audo A, Bonato V, Cavozza C, Maj G, Pittis G, Secco GG. Acute pulmonary embolism in SARS-CoV-2 infection treated with surgical embolectomy. Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athoracsurg.2020.04.013.

23. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging. 2020;101:321–2.

24. Jafri R, Cegolini L, Jafar I, Kashkai M, Otukesh B, Ghaedherijani BH, et al. Large saddle pulmonary embolism in a woman infected by COVID-19 pneumonia. Eur Heart J. 2020;41:2133–4.

25. Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, et al. Pulmonary embolism and increased levels of D-dimer in patients with coronavirus disease. Emerg Infect Dis. 2020;26(8):1941.

26. Martiniell I, Ferrera E, Gavaraile A, Erra R, Iurfaro E, Ossola M, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36–7.

27. Lushina N, Kuo JS, Shaikh HA. Pulmonary, cerebral, and renal thromboembolic disease associated with COVID-19 infection. Radiology. 2020;289:E181–3.

28. Hansch IA, Skiba M, Konturek PC. SARS-CoV-2 pneumonia and pulmonary embolism in a 66-year-old female. Pol Arch Intern Med. 2020;190:438–9.

29. Ueki Y, Otsuka T, Windecker S, Raber L. ST-elevation myocardial infarction and pulmonary embolism in a patient with COVID-19-associated severe respiratory distress syndrome. Eur Heart J. 2020;41:1234.

30. Ioan AM, Durante-Lopez A, Martinez-Milla J, Perez-Calvo C, Santos A. Pulmonary embolism in COVID-19. When nothing is what it seems. Rev Esp Cardiol. 2020;73:665–7.

31. Bruggermann R, Gietema H, Jallal B, Ten Cate H, Stehouwer C, Spaetgens B. Arterial and venous thromboembolic disease in a patient with COVID-19: a case report. Thromb Res. 2020;191:153–5.

32. Perez-Girbes A. Acute pulmonary embolism and COVID-19: a common association in seriously ill patients? Arch Bronconeumol. 2020;56:34.

33. Khodamoradi Z, Boogar SS, Shnazi FKH, Kouhi P. COVID-19 and Acute pulmonary embolism in postpartum patient. Emerg Infect Dis. 2020;26(8):1937–9.
43. Galeano-Valle F, Oblitas CM, Ferreiro-Mazon MM, Alonso-Munoz J, Del Toro-Cervera J, Dremel-Rodriguez P. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113–5.

44. Stoneham SM, Milne KM, Nuttal E, Few GH, Sturrock RD, Sivaloganathan H, et al. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med. 2020;20:e76–81.

45. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020. https://doi.org/10.7326/M20-2566.

46. Rouhezamin MR, Haseli S. Diagnosing pulmonary thromboembolism in COVID-19: a stepwise clinical and imaging approach. Acad Radiol. 2020;27:896–7.

47. Bilkedil B, Madhavhan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;76:2950–2973.

48. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Thromb Haemost. 2020;120:844–7.

49. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–6.

50. Oudkerk M, Buller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC, et al. Diagnosis, prevention, and treatment of thrombotic thrombocytopenic purpura in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. 2020. https://doi.org/10.1148/radiol.2020201629.

51. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421–4.

52. Lippi G, Favaloro EJ. d-Dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost. 2020;120(5):876–8.

53. Thachil J, Srivistava A. SARS-2 Coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost. 2020. https://doi.org/10.1055/s-0040-1712155.

54. Maas C, Renne T. Coagulation factor XII in thrombosis and inflammation. Blood. 2018;131(17):1903–9.

55. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014;123(18):2759–67.

56. Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M. Bronchoalveolar hemorrhage in lung injury and acute respiratory distress syndrome. J Thromb Haemost. 2013;11(1):17–25.

57. Varatharajah N, Rajah S. Microthrombotic complications of COVID-19 are likely due to embolism of circulating endothelial derived ultralarge von willebrand factor (eULWF) decorated-platelet strings. Fed Pract. 2020;37(6):e1–2.

58. Mosleh W, Chen K, Pfau SE, Vashti A. Endotheliitis and endothelial dysfunction in patients with COVID-19: its role in thrombosis and adverse outcomes. J Clin Med. 2020;9(6):1862.

59. Delabranche X, Quenot JP, Lavigne T, Mercier E, Francois B, Severac F, et al. Early detection of disseminated intravascular coagulation during septic shock: a multicenter prospective study. Crit Care Med. 2016;44(10):e830–9.

60. Kollas A, Kyniakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189:846–7.

61. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017;69(6):815–26.

62. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients. COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.

63. Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, et al. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. Thromb Haemost. 2006;96(1):100–1.

64. Zucoloto AZ, Jene CN. Platelet-neutrophil interplay: insights into neutrophil extracellular trap (NET)-driven coagulation in infection. Front Cardiovasc Med. 2019;6:85.

65. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9(5):1417.

66. De Lorenzo A, Escobar S, Tibirica E. Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular and metabolic diseases. Nutr Metab Cardiovasc Dis. 2020;30:1401–2.

67. Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, et al. Elevated serum endothelial cell adhesion molecules expression in COVID-19 patients. J Infect Dis. 2020;222:894–8.

68. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–9.

69. Syropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1859–65.

70. Obi AT, Barnes GD, Wakefield TW, Brown Rvt S, Eliason JL, Arndt E, et al. Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. J Vasc Surg Venous Lymphat Disord. 2020;8:526–34.

71. Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–91.

72. Keshari RS, Silasi R, Popescu NU, Georgescu C, Chaaban H, Lupu C, et al. Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. J Thromb Haemost. 2020;18(1):180–90.

73. Marietta M, Ageno W, Antoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18:167–9.

74. Pannucci CJ, Fleming KL, Holodya K, Moulton L, Prazak AM, Varghese TK, Jr. Enoxaparin 40 mg per day is inadequate for venous thromboembolism prophylaxis after thoracic surgical procedure. Ann Thorac Surg. 2018;106(2):404–11.

75. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111(1):88–93.

76. Zhai Z, Li C, Chen Y, Gerotzlfas G, Zhang Z, Wan J, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. 2020;120:937–48.

77. GJ G, MV H, HC T, MK. Overzetten VKA naar DOAC tijdens corona epidemie. Nutr Metab Cardiovasc Dis. 2020;30:896–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.